IDL-2965: A Selective, highly-potent, oral Integrin antagonist for IPF
K. Kossen (Cambridge, United States of America), C. Schaefer (Cambridge, United States of America), S. Lim (Cambridge, United States of America), M. Michener (Cambridge, United States of America), P. Ruminiski (Cambridge, United States of America), D. Griggs (Cambridge, United States of America), R. Radhakrishnan (Cambridge, United States of America), B. Bradford (Cambridge, United States of America), S. Seiwert (Cambridge, United States of America)
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Session: Translational aspects of idiopathic pulmonary fibrosis
Session type: Poster Discussion
Number: 5374
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Kossen (Cambridge, United States of America), C. Schaefer (Cambridge, United States of America), S. Lim (Cambridge, United States of America), M. Michener (Cambridge, United States of America), P. Ruminiski (Cambridge, United States of America), D. Griggs (Cambridge, United States of America), R. Radhakrishnan (Cambridge, United States of America), B. Bradford (Cambridge, United States of America), S. Seiwert (Cambridge, United States of America). IDL-2965: A Selective, highly-potent, oral Integrin antagonist for IPF. 5374
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Late Breaking Abstract - PK/PD assessment of an oral, selective aVß6/aVß1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019
Selective versus non-selective endothelin receptor antagonists Source: Annual Congress 2005 - New treatments in pulmonary hypertension Year: 2005
Anti-inflammatory effects of roflumilast N-oxide and dexamethasone in human bronchial epithelial cells stimulated with toll-like receptor agonists Source: Annual Congress 2013 –The pulmonary epithelium: recent developments Year: 2013
Effects of oral SCH 527123, a CXCR2 antagonist, on acquired immunity in healthy adults Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007
Late Breaking Abstract: Anti-fibrogenic effects of the endothelin-A receptor antagonist ambrisentan in a mouse pulmonary fibrosis model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
An orally available, highly selective 5-hydroxytryptamine 2B (5-HT2B) receptor antagonist ameliorating pulmonary and dermal fibrosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019
Inhibitory effect of PGE2 receptor subtype, EP4, in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2007 - Mechanisms of injury and repair in fibrotic, idiopathic or infectious lung disease Year: 2007
Role of leukotriene receptor antagonist on TGF-β1 and Smad signalling in bleomycin induced pulmonary fibrosis Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009
Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
An oral selective M3 cholinergic receptor antagonist in COPD Source: Eur Respir J 2006 Oct 01;28(4):772-780 Year: 2006
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids Source: Eur Respir J, 50 (2) 1700670; 10.1183/13993003.00670-2017 Year: 2017
Biosynthesis and implementation of Thyroid Receptor beta (TRß) agonists (thyromimetics) for the treatment of pulmonary fibrosis Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis Year: 2021
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice Source: Eur Respir J 2008; 32: 426-436 Year: 2008
Protective effect of a Protein Epitope Mimetic (PEM) CXCR4 antagonist, POL5551, in an allergic model of asthma Source: Annual Congress 2010 - Models of airways disease Year: 2010